Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.25 - $25.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)230.72K
Market Cap
$533.91M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-6.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,124,393
10 Day Avg. Volume263,029
30 Day Avg. Volume230,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.50Price Target Upside177.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSION's NBD1 pipeline represents the first candidates in this class to successfully enter clinical trials.
Financial PositionProforma cash of ~$351M will provide OpEx runway into 2028.
Market PotentialSION's rigorous clinical work with their two lead NBD1 stabilizers stands up to scrutiny, with the CF market approaching ~$11B, presenting a favorable risk/reward scenario.
Bears Say
Financial Performance4Q24 net loss of $15.8M.
Market CompetitionThe bear case centers around Vertex’s dominance of the CF market, raising questions about SION's ability to realistically compete.
---
Options Prices
Currently, No data available
---
Ownership Overview
53.97% Insiders
―
Mutual Funds
― Other Institutional Investors
46.03% Public Companies and
Individual Investors
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $11.25 and its highest was $25.19 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $533.91M.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Mar 20, 2025. The company reported -$3.38 earnings per share for the quarter, missing the consensus estimate of -$1.277 by -$2.103.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 44,124,393 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$3.38 in its last earnings report, missing expectations of -$1.277. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
---
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTR's nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models.
---
SION Stock 12 Month Forecast
Average Price Target
$38.50
▲(177.38% Upside)
Technical Analysis
Best Analysts Covering SION
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-18.20%
reiterated a buy rating 5 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -18.20% per trade.
---